Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

被引：1
|
作者：
Gan, Chun Loo
Wells, J. Connor
Schmidt, Andrew Lachlan
Powles, Thomas
Tran, Ben
Meza, Luis A.
Labaki, Chris
Lee, Jae-Lyun
Wood, Lori
Shapiro, Julia
Ernst, D. Scott
Kapoor, Anil
Canil, Christina M.
Yuasa, Takeshi
McKay, Rana R.
Beuselinck, Benoit
Donskov, Frede
Dudani, Shaan
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Univ Calgary, Calgary, AB, Canada
[3] Cairns & Hinterland Hosp & Hlth Serv, Liz Plummer Canc Ctr, Cairns, Qld, Australia
[4] Queen Mary Univ London, Royal Free Natl Hlth Serv Trust, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] City Hope Comprehens Canc Ctr, Duarte, CA USA
[7] Dana Farber Canc Inst Individuals, Boston, MA USA
[8] Asan Med Ctr, Seoul, South Korea
[9] Univ Ulsan, Coll Med, Seoul, South Korea
[10] Dalhousie Univ, Halifax, NS, Canada
[11] Cabrini Hlth, Melbourne, Vic, Australia
[12] London Hlth Sci Ctr, London Reg Canc Program, Dept Oncol, Div Med Oncol, London, ON, Canada
[13] Univ Western Ontario, London, ON, Canada
[14] St Josephs Healthcare, McMaster Inst Urol, Hamilton, ON, Canada
[15] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[16] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[17] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[18] Univ Ziekenhuizen, Leuven Canc Inst, Leuven, Belgium
[19] Aarhus Univ Hosp, Aarhus, Denmark
[20] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[21] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4554
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).
    Li, Haoran
    Choueiri, Toni K.
    Wells, Connor
    Agarwal, Neeraj
    Donskov, Frede
    Lee, Jae-Lyun
    Broom, Reuben James
    Yuasa, Takeshi
    Rini, Brian I.
    Pal, Sumanta Kumar
    Wood, Lori
    Ernst, D. Scott
    Kollmannsberger, Christian K.
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Saleem, Sadia
    Beuselinck, Benoit
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
    Gul, Anita
    Shah, Neil J.
    Mantia, Charlene
    Hammers, Hans J.
    Ornstein, Moshe Chaim
    McDermott, David F.
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [23] Sites of metastasis and survival in metastatic renal-cell carcinoma (mRCC): Resuits from the international mRCC Database Consortium (IMDC)
    Dudani, Shaan
    de Velasco, Guillermo
    Wells, J. Connor
    Gan, Chun Loo
    Donskov, Frede
    Porta, Camillo
    Fraccon, Anna
    Pasini, Felice
    Hansen, Aaron
    Bjarnason, Georg
    Beuselinck, Benoit
    Pal, Sumanta K.
    Hotte, Sebastien
    Lalani, Aly-Khan A.
    Yuasa, Takeshi
    Kanesvaran, Ravindran
    Reaume, M. Neil
    Canil, Christina
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 4 - 4
  • [24] Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
    Ali, Sana
    Leong, Sally
    Meza, Luis A.
    Dizman, Nazli
    Zengin, Zeynep Busra
    Kim, Tane
    Pak, Youngju
    Onyshchenko, Mykola
    Pal, Sumanta K.
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Roussel, Eduard
    Kinget, Lisa
    Beuselinck, Benoit
    Albersen, Maarten
    Wells, Connor
    Ernst, Matthew Scott
    Donskov, Frede
    Schmidt, Andrew Lachlan
    Szabados, Bernadett
    Pal, Sumanta K.
    Meza, Luis A.
    Agarwal, Neeraj
    Weickhardt, Andrew James
    Davis, Ian D.
    Alva, Ajjai Shivaram
    Wood, Lori
    Porta, Camillo
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Navani, Vishal
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT)
    Ko, Jenny J.
    Xie, Wanling
    Heng, Daniel Yick Chin
    Kroeger, Nils
    Lee, Jae-Lyun
    Rini, Brian I.
    Knox, Jennifer J.
    Bjarnason, Georg A.
    Harshman, Lauren Christine
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Smoragiewicz, Martin
    Donskov, Frede
    Bamias, Aristotelis
    Wood, Lori
    Ernst, D. Scott
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
    Leong, Sally
    Ali, Sana
    Zengin, Zeynep Busra
    Meza, Luis A.
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Govindarajan, Ameish
    Castro, Daniela V.
    Li, Xiaochen
    Kim, Tane
    Melamed, Sam
    Pal, Sumanta Monty
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Gebrael, Georges
    Saad, Eddy
    Labaki, Chris
    Saliby, Renee Maria
    Sayegh, Nicolas
    Wells, J. Connor
    Semaan, Karl
    Eid, Marc
    Takemura, Kosuke
    Ernst, Matthew Scott
    Lemelin, Audreylie
    Basappa, Naveen S.
    Wood, Lori
    Powles, Thomas
    Ernst, D. Scott
    Kapoor, Anil
    Xie, Wanling
    Agarwal, Neeraj
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
    Heng, Daniel Yick Chin
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Yamamoto, Haru
    Ernst, D. Scott
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor
    Donskov, Frede
    Pal, Sumanta K.
    Dizman, Nazli
    Rathi, Nityam
    Beuselinck, Benoit
    Yan, Flora
    Lalani, Aly-Khan A.
    Hansen, Aaron Richard
    Szabados, Bernadett
    de Velasco, Guillermo
    Tran, Ben
    Lee, Jae-Lyun
    Vaishampayan, Ulka N.
    Bjarnason, Georg A.
    Subasri, Mathushan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345